Key Highlights
- Oxford Nanopore Technologies Plc (LSE:ONT) shares gained 4.91% on 6 October 2026, trading around 232p and setting a new 52-week high.
- The stock has rallied sharply since late September, rising from about 182p to above 230p in roughly a week.
- A Unified Patent Court preliminary injunction against MGI Tech GmbH on 16 September 2026 strengthened the company's competitive position.
- An analyst price target increase to 210p on 22 September 2026 helped spark the re-rating, which the shares have since surpassed.
- IP Group sold 10 million shares on 2 October but kept a 7.23% stake and agreed a 90-day lock-up.
Why Oxford Nanopore (LSE:ONT) Shares Are Rising
Oxford Nanopore Technologies Plc (LSE:ONT) added 4.91% on 6 October 2026, pushing the shares to around 232p and extending one of the strongest runs on the FTSE 250 in recent weeks. The DNA and RNA sequencing specialist has been buoyed by a confluence of supportive factors: a significant intellectual property legal victory, analyst momentum, insider buying, and growing confidence in the strategy set out by new chief executive Francis Van Parys.
The momentum has been striking. Over a two-week period, the shares moved from about 173p to 182p, then jumped to 199.4p and 217.6p in successive sessions at the end of September, touching an intraday high of 218.4p before consolidating near 214p. The latest gain takes the stock decisively into new 52-week high territory and reflects a near-doubling from its cycle lows of around 96p.
Patent Victory Over MGI
On 16 September 2026 the Unified Patent Court granted Oxford Nanopore a preliminary injunction against MGI Tech GmbH, a Subsidiary of the Chinese sequencing group. Oxford Nanopore had confirmed earlier in the year that patent proceedings were underway against MGI, with a full trial set for 2027. The injunction reinforces the company's competitive moat in nanopore sequencing and signals that its extensive patent estate can be enforced in key European markets.
Analyst Upgrades and Insider Buying
On 22 September 2026, an analyst raised the price target on Oxford Nanopore to 210p from 195p while maintaining a buy rating. The stock has since broken convincingly above that level, implying the market is pricing in further upside. Insider share purchases of nearly 16,000 shares in recent months have also signalled management confidence.
IP Group Stake Sale: An Overhang Cleared
On 2 October 2026, IP Group, a founding investor that provided seed funding in 2005, sold 10 million Oxford Nanopore shares, raising about £21 million. It retains 70.8 million shares, or 7.23% of the company, worth around £151.5 million, plus about 11.8 million shares held through managed funds. Importantly, IP Group agreed a 90-day lock-up on its remaining direct holding. The market absorbed the placing smoothly, and the lock-up removes a near-term Supply concern, which supported the latest leg higher.
Strategy and Financial Progress
Francis Van Parys took over as CEO in March 2026, succeeding co-founder Gordon Sanghera. In August 2026 he set out an ambition for more than US$700 million in Revenue by 2030 and a longer-term sales target of US$1 billion, focusing on the most lucrative sequencing opportunities, including quality control for mRNA vaccines, clinical and biopharma applications.
First-half 2026 results showed revenue of £116.7 million, up 12.3% at constant currency, though below management's expectations due to weakness in China and the Middle East. However, gross Margin jumped 400 basis points to 62.2%, and the adjusted EBITDA loss halved to £22.1 million from £48.3 million. The company reaffirmed targets of adjusted EBITDA breakeven in 2027 and positive free Cash Flow in 2028.
New management hires include David Miller, formerly head of R&D at Pacific Biosciences, and Conor McKechnie, who joined as Chief Marketing and Communications Officer on 1 October 2026.
Why Investors Are Watching LSE:ONT
- Path to profitability: EBITDA breakeven targeted for 2027 with sharply improving margins.
- IP strength: The MGI injunction validates the company's patent position.
- Clinical growth: Clinical and biopharma revenues have been growing rapidly.
- Strategic clarity: A focused portfolio and US$1 billion long-term revenue ambition.
- Momentum: The stock is trading at its highest level in more than a year.
Risks to Consider
Oxford Nanopore remains loss-making, and revenue missed expectations in the first half. Competition in sequencing from larger rivals is intense, and weakness in China and the Middle East could persist. After such a steep rally, the shares may be vulnerable to profit-taking. The MGI trial in 2027 still carries legal uncertainty.
Outlook
The next catalysts include any trading updates ahead of full-year results, further legal developments, and commercial progress in clinical and biopharma markets. Investors will also watch whether the company can keep improving margins while returning to faster revenue growth.






Please wait processing your request...